DE69634859D1 - Induktion von immunologischer toleranz - Google Patents

Induktion von immunologischer toleranz

Info

Publication number
DE69634859D1
DE69634859D1 DE69634859T DE69634859T DE69634859D1 DE 69634859 D1 DE69634859 D1 DE 69634859D1 DE 69634859 T DE69634859 T DE 69634859T DE 69634859 T DE69634859 T DE 69634859T DE 69634859 D1 DE69634859 D1 DE 69634859D1
Authority
DE
Germany
Prior art keywords
tissue
implanted
cell
induction
organs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69634859T
Other languages
English (en)
Inventor
Paul P Latta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69634859D1 publication Critical patent/DE69634859D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
DE69634859T 1995-10-26 1996-10-25 Induktion von immunologischer toleranz Expired - Lifetime DE69634859D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US587795P 1995-10-26 1995-10-26
PCT/US1996/017234 WO1997015243A1 (en) 1995-10-26 1996-10-25 Induction of immunological tolerance

Publications (1)

Publication Number Publication Date
DE69634859D1 true DE69634859D1 (de) 2005-07-21

Family

ID=21718169

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69637842T Expired - Lifetime DE69637842D1 (de) 1995-10-26 1996-10-25 Induktion von immunologischer Toleranz
DE69634859T Expired - Lifetime DE69634859D1 (de) 1995-10-26 1996-10-25 Induktion von immunologischer toleranz

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69637842T Expired - Lifetime DE69637842D1 (de) 1995-10-26 1996-10-25 Induktion von immunologischer Toleranz

Country Status (6)

Country Link
US (5) US20020192190A1 (de)
EP (2) EP1586284B1 (de)
AT (2) ATE422857T1 (de)
AU (1) AU7479596A (de)
DE (2) DE69637842D1 (de)
WO (1) WO1997015243A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69637842D1 (de) * 1995-10-26 2009-04-02 Paul P Latta Induktion von immunologischer Toleranz
WO2000054786A1 (en) * 1999-03-15 2000-09-21 Modex Therapeutiques, S.A. Methods and compositions for tolerizing hosts for long term survival of tissue transplants
US20020012667A1 (en) * 2000-05-16 2002-01-31 Mcmichael John Method for preventing allograft rejection
CA2662209C (en) * 2006-08-29 2015-02-17 The University Of Akron Implantable devices for producing insulin
US20100196439A1 (en) * 2006-12-22 2010-08-05 Medtronic, Inc. Angiogenesis Mechanism and Method, and Implantable Device
ES2409180T3 (es) * 2007-10-15 2013-06-25 Fresenius Medical Care Deutschland Gmbh Uso de microvesículas (MVS), para preparar un medicamento que tiene actividad de adyuvante en el trasplante de células endoteliales, particularmente en el tratamiento de la diabetes mediante el trasplante de islotes pancreáticos,y método relacionado
US9540630B2 (en) * 2008-09-17 2017-01-10 Beta O2 Technologies Ltd. Optimization of alginate encapsulation of islets for transplantation
EA025142B1 (ru) 2009-08-28 2016-11-30 Сернова Корпорэйнш Способ и устройство для клеточной трансплантации
WO2011154941A2 (en) 2010-06-07 2011-12-15 Beta-O2 Technologies Ltd. Multiple-layer immune barrier for donor cells
US20190224377A1 (en) 2016-10-05 2019-07-25 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and systems for augmenting immune system responses
US10973956B2 (en) * 2017-01-05 2021-04-13 The Regents Of The University Of Michigan Microporous hydrogel scaffolds for cell transplantation

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4298002A (en) 1979-09-10 1981-11-03 National Patent Development Corporation Porous hydrophilic materials, chambers therefrom, and devices comprising such chambers and biologically active tissue and methods of preparation
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4378016A (en) 1981-07-15 1983-03-29 Biotek, Inc. Artificial endocrine gland containing hormone-producing cells
CA1196862A (en) 1983-06-01 1985-11-19 Anthony M.F. Sun Microencapsulation of living tissue and cells
US4689293A (en) 1983-06-06 1987-08-25 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US4806355A (en) 1983-06-06 1989-02-21 Connaught Laboratories Limited Microencapsulation of living tissue and cells
EP0147939A2 (de) 1983-11-15 1985-07-10 JOHNSON & JOHNSON Einpflanzbarer Modul zur Regulierung der Glykämie
NO166836C (no) 1985-03-14 1991-09-11 Univ California Fremgangsmaate for behandling av et organtransplantat.
US4997443A (en) 1985-08-26 1991-03-05 Hana Biologics, Inc. Transplantable artificial tissue and process
US4902295A (en) 1985-08-26 1990-02-20 Hana Biologics, Inc. Transplantable artificial tissue
GB8608068D0 (en) * 1986-04-02 1986-05-08 Cobbold S P Monoclonal antibodies
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5182111A (en) 1987-11-17 1993-01-26 Boston University Research Foundation In vivo delivery of active factors by co-cultured cell implants
JP3117994B2 (ja) 1990-05-16 2000-12-18 ベイラー・カレツジ・オブ・メデイシン 永久的ヒト肝細胞の細胞系および肝臓補助装置（ｌａｄ）におけるその使用
US5529914A (en) * 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
CA2034641A1 (en) 1990-11-27 1992-05-28 Gudmund Skjak-Braek Homologous guluronic acid alginate coating composition for in-vivo application and implatation and method of using same
CA2109085C (en) 1991-04-25 2003-03-11 Keith E. Dionne Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
GB9120776D0 (en) 1991-10-01 1991-11-13 Shell Int Research Process for upgrading a hydrocarbonaceous feedstock and apparatus for use therein
US5425764A (en) * 1992-07-30 1995-06-20 The University Of Toledo Bioartificial pancreas
US5262055A (en) * 1992-10-19 1993-11-16 The University Of Utah Implantable and refillable biohybrid artificial pancreas
WO1995003062A1 (en) * 1993-07-21 1995-02-02 Cellpro, Incorporated Methods and compositions for preventing immune rejection of solid organ grafts
US6703017B1 (en) * 1994-04-28 2004-03-09 Ixion Biotechnology, Inc. Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
US5629194A (en) * 1994-10-21 1997-05-13 Diacrin, Inc. Isolated porcine pancreatic cells for use in treatment of diseases characterized by insufficient insulin activity
DE69637842D1 (de) * 1995-10-26 2009-04-02 Paul P Latta Induktion von immunologischer Toleranz

Also Published As

Publication number Publication date
WO1997015243A1 (en) 1997-05-01
EP0955948B1 (de) 2005-06-15
ATE297702T1 (de) 2005-07-15
US20040047848A1 (en) 2004-03-11
EP1586284B1 (de) 2009-02-18
DE69637842D1 (de) 2009-04-02
EP1586284A1 (de) 2005-10-19
AU7479596A (en) 1997-05-15
EP0955948A4 (de) 1999-11-17
US7361334B2 (en) 2008-04-22
US20100260816A1 (en) 2010-10-14
US20020192190A1 (en) 2002-12-19
US20040191227A1 (en) 2004-09-30
US7361333B2 (en) 2008-04-22
ATE422857T1 (de) 2009-03-15
EP0955948A1 (de) 1999-11-17
US20080317770A1 (en) 2008-12-25

Similar Documents

Publication Publication Date Title
DK0920322T3 (da) Anvendelser af modificeret autologt blod til behandling af autoimmunitetssygdomme
ATE308926T1 (de) Nicht antigenische und durch peressigsäure vernetzte transplantate mit innerer kollagenschicht
DE69714083D1 (de) Die verwendung von lactoperoxidase, einem peroxiddonor und thiocyanat zur herstellung eines medikaments zur behandlung einer infektion mit helicobacter pylori
ES2192623T3 (es) Implante medico.
EP0128706A3 (de) Körperimplantate einer extracellulären Matrix sowie Mittel und Methoden zur Herstellung und Verwendung solcher Implantate
ATE142693T1 (de) Herstellung des vaskulären endothelialen zellwachstumsfaktors
FR2701648B1 (fr) Prothèse destinée au traitement d'une lumière ou voie naturelle, notamment prothèse endo-uréthrale.
DE69637842D1 (de) Induktion von immunologischer Toleranz
AU6649996A (en) Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
DE69840913D1 (de) Divalent anti-t-zellen immuntoxinen und deren verwendung
DE69738692D1 (de) LO-CD2a ANTIKÖRPER UND DESSEN VERWENDUNGEN ZUR HEM
KR950700079A (ko) 이식체-대-숙주 질환을 억제하기 위한 인터루킨-10의 용도(Use of interleukin-10 to suppress graft-vs. -host disease)
PT941329E (pt) Metodo para prevenir a rejeicao de enxertos em transplantacao e para produzir uma celula-hospedeiro para terapia genetica universal utilizando activacao de linfocitos (lag-3)
PT841939E (pt) Agentes terapeuticos e doencas auto-imunes
DK0768886T3 (da) Endothelforingseffekter og behandling af vasospastiske lidelser
DE69638145D1 (de) Verfahren zur herbeiführung einer immuntoleranz mit hilfe von immuntoxinen
DE69428272D1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
ATE261735T1 (de) Verwendung von wirkstoffen zur herstellung von arzeinmitteln zur behandlung der rheumatischen arthritis
GB9617611D0 (en) Treatment of autoimmune disease
developing counties like India Prof. Dr. Ashraf Ganatra
Grant DUHIKYA: THE HOPI HEALER.
PEER et al. Behavior of a first, second and third crop of skin homografts from the same donor
DE3877102T2 (de) Methode fuer die behandlung von viraler gehirnentzuendung.
ORA SATURDAY MAY 26 1951
Levy et al. Gerontology and the Practice of Geriatric Dentistry 1

Legal Events

Date Code Title Description
8332 No legal effect for de